DARE
Dare Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+0.22%Year over year
Reported trailing growth
- Revenue
- +7816.7%
- EBITDA
- +50.9%
- EBIT
- +39.9%
- EPS
- +63.3%
- Free cash flow
- +1.0%
- Operating cash flow
- +2.5%
Forward estimates
Based on analyst estimates
- Revenue
- +250.8%
- EBITDA
- +19.5%
- EPS
- +20.4%
Three-year CAGR
- Revenue
- -53.1%
- EBITDA
- —
- EBIT
- +42.2%
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026